Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment

Robert Marx, Joseph E. Cillo, Juan J. Ulloa

Research output: Contribution to journalArticle

493 Citations (Scopus)

Abstract

Purpose: To assess the risk and time course of oral bisphosphonate-induced osteonecrosis of the jaws. Materials and Methods: Detailed data from 30 consecutive cases were compared with 116 cases due to intravenous aminobisphosphonates. Results: Results in part noted a higher incidence related to alendronate (Fosamax; Merck, Whitehouse Station, NJ), a 94.7% predilection for the posterior mandible, and a 50% occurrence spontaneously, with the remaining 50% resulting from an oral surgical procedure, mostly tooth removals. Just over 53% of patients were taking their oral bisphosphonate for osteopenia, 33.3% for documented osteoporosis, and 13.4% for steroid-induced osteoporosis related to 4 or more years of prednisone therapy for an autoimmune condition. There was a direct exponential relationship between the size of the exposed bone and the duration of oral bisphosphonate use. There was also a direct correlation between reports of pain and clinical evidence of infection. The morning fasting serum C-terminal telopeptide (CTX) test results were observed to correlate to the duration of oral bisphosphonate use and could indicate a recovery of bone remodeling with increased values if the oral bisphosphonate was discontinued. A stratification of relative risk was seen as CTX values less than 100 pg/mL representing high risk, CTX values between 100 pg/mL and 150 pg/mL representing moderate risk, and CTX values above 150 pg/mL representing minimal risk. The CTX values were noted to increase between 25.9 pg/mL to 26.4 pg/mL for each month of a drug holiday indicating a recovery of bone remodeling and a guideline as to when oral surgical procedures can be accomplished with the least risk. In addition, drug holidays associated with CTX values rising above the 150 pg/mL threshold were observed to correlate to either spontaneous bone healing or a complete healing response after an office-based debridement procedure. Conclusions: Oral bisphosphonate-induced osteonecrosis is a rare but real entity that is less frequent, less severe, more predictable, and more responsive to treatment than intravenous bisphosphonate-induced osteonecrosis. The morning fasting serum C-terminal telopeptide bone suppression marker is a useful tool for the clinician to assess risks and guide treatment decisions.

Original languageEnglish
Pages (from-to)2397-2410
Number of pages14
JournalJournal of Oral and Maxillofacial Surgery
Volume65
Issue number12
DOIs
StatePublished - Dec 1 2007

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Diphosphonates
Serum
Oral Surgical Procedures
Alendronate
Holidays
Bone Remodeling
Bone and Bones
Therapeutics
Osteoporosis
Fasting
Metabolic Bone Diseases
Debridement
Prednisone
Mandible
Pharmaceutical Preparations
Tooth
Steroids
Guidelines
Pain

ASJC Scopus subject areas

  • Dentistry(all)
  • Surgery

Cite this

Oral Bisphosphonate-Induced Osteonecrosis : Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment. / Marx, Robert; Cillo, Joseph E.; Ulloa, Juan J.

In: Journal of Oral and Maxillofacial Surgery, Vol. 65, No. 12, 01.12.2007, p. 2397-2410.

Research output: Contribution to journalArticle

@article{ae8848489f0247f9b86f3300088dabea,
title = "Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment",
abstract = "Purpose: To assess the risk and time course of oral bisphosphonate-induced osteonecrosis of the jaws. Materials and Methods: Detailed data from 30 consecutive cases were compared with 116 cases due to intravenous aminobisphosphonates. Results: Results in part noted a higher incidence related to alendronate (Fosamax; Merck, Whitehouse Station, NJ), a 94.7{\%} predilection for the posterior mandible, and a 50{\%} occurrence spontaneously, with the remaining 50{\%} resulting from an oral surgical procedure, mostly tooth removals. Just over 53{\%} of patients were taking their oral bisphosphonate for osteopenia, 33.3{\%} for documented osteoporosis, and 13.4{\%} for steroid-induced osteoporosis related to 4 or more years of prednisone therapy for an autoimmune condition. There was a direct exponential relationship between the size of the exposed bone and the duration of oral bisphosphonate use. There was also a direct correlation between reports of pain and clinical evidence of infection. The morning fasting serum C-terminal telopeptide (CTX) test results were observed to correlate to the duration of oral bisphosphonate use and could indicate a recovery of bone remodeling with increased values if the oral bisphosphonate was discontinued. A stratification of relative risk was seen as CTX values less than 100 pg/mL representing high risk, CTX values between 100 pg/mL and 150 pg/mL representing moderate risk, and CTX values above 150 pg/mL representing minimal risk. The CTX values were noted to increase between 25.9 pg/mL to 26.4 pg/mL for each month of a drug holiday indicating a recovery of bone remodeling and a guideline as to when oral surgical procedures can be accomplished with the least risk. In addition, drug holidays associated with CTX values rising above the 150 pg/mL threshold were observed to correlate to either spontaneous bone healing or a complete healing response after an office-based debridement procedure. Conclusions: Oral bisphosphonate-induced osteonecrosis is a rare but real entity that is less frequent, less severe, more predictable, and more responsive to treatment than intravenous bisphosphonate-induced osteonecrosis. The morning fasting serum C-terminal telopeptide bone suppression marker is a useful tool for the clinician to assess risks and guide treatment decisions.",
author = "Robert Marx and Cillo, {Joseph E.} and Ulloa, {Juan J.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.joms.2007.08.003",
language = "English",
volume = "65",
pages = "2397--2410",
journal = "Journal of Oral and Maxillofacial Surgery",
issn = "0278-2391",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Oral Bisphosphonate-Induced Osteonecrosis

T2 - Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment

AU - Marx, Robert

AU - Cillo, Joseph E.

AU - Ulloa, Juan J.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: To assess the risk and time course of oral bisphosphonate-induced osteonecrosis of the jaws. Materials and Methods: Detailed data from 30 consecutive cases were compared with 116 cases due to intravenous aminobisphosphonates. Results: Results in part noted a higher incidence related to alendronate (Fosamax; Merck, Whitehouse Station, NJ), a 94.7% predilection for the posterior mandible, and a 50% occurrence spontaneously, with the remaining 50% resulting from an oral surgical procedure, mostly tooth removals. Just over 53% of patients were taking their oral bisphosphonate for osteopenia, 33.3% for documented osteoporosis, and 13.4% for steroid-induced osteoporosis related to 4 or more years of prednisone therapy for an autoimmune condition. There was a direct exponential relationship between the size of the exposed bone and the duration of oral bisphosphonate use. There was also a direct correlation between reports of pain and clinical evidence of infection. The morning fasting serum C-terminal telopeptide (CTX) test results were observed to correlate to the duration of oral bisphosphonate use and could indicate a recovery of bone remodeling with increased values if the oral bisphosphonate was discontinued. A stratification of relative risk was seen as CTX values less than 100 pg/mL representing high risk, CTX values between 100 pg/mL and 150 pg/mL representing moderate risk, and CTX values above 150 pg/mL representing minimal risk. The CTX values were noted to increase between 25.9 pg/mL to 26.4 pg/mL for each month of a drug holiday indicating a recovery of bone remodeling and a guideline as to when oral surgical procedures can be accomplished with the least risk. In addition, drug holidays associated with CTX values rising above the 150 pg/mL threshold were observed to correlate to either spontaneous bone healing or a complete healing response after an office-based debridement procedure. Conclusions: Oral bisphosphonate-induced osteonecrosis is a rare but real entity that is less frequent, less severe, more predictable, and more responsive to treatment than intravenous bisphosphonate-induced osteonecrosis. The morning fasting serum C-terminal telopeptide bone suppression marker is a useful tool for the clinician to assess risks and guide treatment decisions.

AB - Purpose: To assess the risk and time course of oral bisphosphonate-induced osteonecrosis of the jaws. Materials and Methods: Detailed data from 30 consecutive cases were compared with 116 cases due to intravenous aminobisphosphonates. Results: Results in part noted a higher incidence related to alendronate (Fosamax; Merck, Whitehouse Station, NJ), a 94.7% predilection for the posterior mandible, and a 50% occurrence spontaneously, with the remaining 50% resulting from an oral surgical procedure, mostly tooth removals. Just over 53% of patients were taking their oral bisphosphonate for osteopenia, 33.3% for documented osteoporosis, and 13.4% for steroid-induced osteoporosis related to 4 or more years of prednisone therapy for an autoimmune condition. There was a direct exponential relationship between the size of the exposed bone and the duration of oral bisphosphonate use. There was also a direct correlation between reports of pain and clinical evidence of infection. The morning fasting serum C-terminal telopeptide (CTX) test results were observed to correlate to the duration of oral bisphosphonate use and could indicate a recovery of bone remodeling with increased values if the oral bisphosphonate was discontinued. A stratification of relative risk was seen as CTX values less than 100 pg/mL representing high risk, CTX values between 100 pg/mL and 150 pg/mL representing moderate risk, and CTX values above 150 pg/mL representing minimal risk. The CTX values were noted to increase between 25.9 pg/mL to 26.4 pg/mL for each month of a drug holiday indicating a recovery of bone remodeling and a guideline as to when oral surgical procedures can be accomplished with the least risk. In addition, drug holidays associated with CTX values rising above the 150 pg/mL threshold were observed to correlate to either spontaneous bone healing or a complete healing response after an office-based debridement procedure. Conclusions: Oral bisphosphonate-induced osteonecrosis is a rare but real entity that is less frequent, less severe, more predictable, and more responsive to treatment than intravenous bisphosphonate-induced osteonecrosis. The morning fasting serum C-terminal telopeptide bone suppression marker is a useful tool for the clinician to assess risks and guide treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=36048931674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36048931674&partnerID=8YFLogxK

U2 - 10.1016/j.joms.2007.08.003

DO - 10.1016/j.joms.2007.08.003

M3 - Article

C2 - 18022461

AN - SCOPUS:36048931674

VL - 65

SP - 2397

EP - 2410

JO - Journal of Oral and Maxillofacial Surgery

JF - Journal of Oral and Maxillofacial Surgery

SN - 0278-2391

IS - 12

ER -